Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986310 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Part 1: BMS-986310 + Nivolumab Combination Dose Escalation Sub-Study A: A cohort of Cisplatin Ineligible Muscle Invasive Bladder Cancer patients will receive either monotherapy BMS-986310, or BMS-986310 + Nivolumab, or Nivolumab monotherapy. Sub-Study B: A cohort of PD\[L\]1 relapsed / refractory tumor cancer patients will be treated with monotherapy BMS-986310 followed by BMS-986310 + nivolumab |
| Cohort Expansion | EXPERIMENTAL | Part 2: Cohort Expansion will initiate upon consideration of the totality of data from Part 1. BMS-986310 + Nivolumab combination will be administered in specific patient populations. |
| Name | Type | Description |
|---|---|---|
| BMS-986310 | DRUG | Specified dose on specified days |
| Nivolumab | BIOLOGICAL | Specified dose on specified days |
Inclusion Criteria: * Patients with measurable disease per RECIST v1.1 and have at least one lesion accessible for biopsy. * ECOG performance status less than or equal to 1 Part 1 and Sub-study B: i) Part 1 participants must have advanced or metastatic disease where no other standard of care trea...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
BMS-986310 is an investigational small molecule being studied for the treatment of advanced cancer, specifically advanced solid tumors. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
BMS-986310 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY.
BMS-986310 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. A Phase 1 study of the drug has been completed.
BMS-986310 has one completed Phase 1 clinical trial, identified as NCT03661632. This study evaluated the drug administered alone and in combination with nivolumab in patients with advanced solid tumors, enrolling 27 participants in the United States, Belgium, and Canada.
BMS-986310 is a small molecule being investigated as an immunotherapy for advanced cancer. The specific molecular target of BMS-986310 has not been disclosed in available information.